Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Senaparib by IMPACT Therapeutics for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Data Insights
Senaparib by IMPACT Therapeutics for Solid Tumor: Likelihood of Approval
Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...